Dr. Coleman has been a faculty member at Farmingdale State College since 2011. His work focuses on rational gene design for vaccine construction - developing vaccines using a software-platform he co-developed. Dr. Coleman’s work successfully applied synthetic gene customization to seven distinct viruses including: poliovirus, Influenza A virus, as well as Streptococcus pneumoniae and Enterotoxigenic E. Coli., controlling their gene expression and constructing live-attenuated vaccine candidates.
He has multiple high-impact publications, is the primary investigator on externally funded research projects, and has project management skills in small business and biotechnology.
Dr. Coleman completed his MBA in finance while simultaneously co-founding Codagenix Inc., and teaching/researching as an assistant professor. Dr. Coleman possess unique knowledge of synthetic biology combined with a cross-functional skill that is strong in science and start-ups companies.
Areas of Expertise (12)
Start Up Companies
Industry Expertise (2)
BioBricks Foundation, Synthetic Biology 5.0, Young Researcher Travel Award (professional)
BioBricks Foundation, Synthetic Biology 5.0, Young Researcher Travel Award
American Foundation for Aging Research (professional)
American Foundation for Aging Research
Theresa Santmann Award – Farmingdale State College (professional)
Theresa Santmann Award – Farmingdale State College
Top 15 Young Entrepreneur of Long Island – Long Island Launch Pad (professional)
Top 15 Young Entrepreneur of Long Island – Long Island Launch Pad
Stony Brook Unviersity: PhD, Molecular Biology
New York Institute of Technology: Masters of Business Administration in Finance, MBA
Tulane University: BS, Cell Biology
Event Appearances (5)
Emerging Vaccine Technologies
ImVacs Boston, MA
Applications of Synthetic Biology
Synthetic Biology 5.0 Stanford University
Recoding Viral RNA Genomes through Chemical Synthesis: Novel Genetics and Practical Applications
Workshop 3: Synthetic Biology Ohio State University
Rapid Development of Vaccines Against Emerging Threats Using DNA Synthesis and Gene Customization
Gordon Research Conference: Chemical and Biological Terrorism Defense Galveston, Texas
Whole Viral Genome Synthesis in Synthetic Biology
Synthetic Biology 4.0 Conference Hong Kong University of Science and Technology
- Workshop Leader
- Corporate Training
Media Appearances (5)
Codagenix snags $322,000 to fund vaccine research
Codagenix, a Stony Brook biotech company, has closed on $322,000 in public and private funding, including the latest round from a coalition promoting Long Island startups. The company, which digitally simulates viruses to produce vaccines, received $100,000 through a joint investment from Accelerate Long Island and the Long Island Emerging Technology Fund. Codagenix also won a $222,000 grant from the National Institutes of Health.
Codagenix snags grant to develop vaccine for foot-and-mouth disease
Codagenix Inc., a Stony Brook biotech company researching new vaccine-making methods, has been awarded nearly $100,000 to help develop a vaccine for foot-and-mouth disease.
LI biotech Codagenix receives $2M equity investment
Codagenix, a biotechnology startup working on commercializing a new flu vaccine-making method, has received a $2 million investment from venture capital firm Topspin Partners of Roslyn Heights.
Codagenix, A Tiny Start-Up Ready To Take On The Goliaths Of The Vaccine Industry
Life Science Leader online
One egg per person. That is what it takes to produce a flu vaccine. The standard, predominant method has not changed in more than 70 years. What has changed dramatically, however, is the per-unit cost of goods, price, and scarcity of the product; all have risen steadily, to the point now where the old model of universal vaccination seems more antiquated than the aforementioned egg. Arguably, newer, recombinant and cell-based production technologies have only compounded the cost/supply dilemma for vaccines, without a commensurate rise in mass efficacy. What if a company had a technology that could sharply lower CoG (cost of goods) and ensure the highest possible availability and effectiveness of an influenza vaccine — even though the company were a David up against the flu-shot Goliaths?
LI wins $98.3M in state business aid
There also was $2.3 million for a vaccine development center at Farmingdale State College that is centered on Codagenix Inc., a flu vaccine developer born at Stony Brook University. Farmingdale State president W. Hubert Keen said faculty, scientists and students are working to create “immunity in biological systems and this funding will assist us enormously in advancing this research.”
Research Grants (4)
NIH Small Business Technology Transfer
Live-attenuated ETEC Anti-Diarrhea Vaccine Construction via Synthetic Biology. The goal of this project is to develop live-attenuated vaccines candidates against the enteric microbial pathogen ETEC.
EAGER: Algorithms for Synthetic Gene Library Design
A grant for the construction of single iterations (i.e. small changes) of a target gene. The goal of this project is to develop a method for high throughput gene design.
NIH Small Business Technology Transfer
Co-wrote a successfully funded STTR “Rational Design of Live Attenuated Influenza A Vaccine Candidates"
Biomedical Research Grant
American Lung Association $74,816
Serve as PI to study the application of synthetic gene design to Streptococcus vaccine construction.
Published Articles (5)
An Ahemolytic Pneumolysin of Streptococcus Pneumoniae Manipulates Human Innate and CD4+ T-Cell Responses and Reduces Resistance to Colonization in Mice in a Serotype-Independent Manner.
Tailoring of the Cellular Immune Response by Synthetic Customization of Pathogen Gene Expression
Antibodies to Streptococcus pneumoniae capsular polysaccharide enhance pneumococcal
Designed Reduction of Streptococcus pneumoniae Pathogenicity via Synthetic Changes in Codon-Pair Bias
Harnessing DNA Synthesis to Develop Rapid Responses to Emerging and Pandemic Pathogens
Biological Principles I
This course deals with biological processes primarily at the molecular and cellular level, and develops the foundations of evolutionary and ecological concepts. There is a study of cell structure, and an examination of cellular composition and metabolic processes including enzyme activity, respiration, and photosynthesis. Principles of genetics are studied at the cellular and molecular level, with reference to current techniques in molecular biology. Evolutionary mechanisms are introduced and ecological concepts are presented as a unifying theme.
Introduction to Bioscience
Moving beyond the basic concepts of general biology, this class explores how biology is used in both academic and commercial settings within the fields of biotechnology, pharmaceutical and clinical sciences. Topics will include: applications of biotechnology in microbes, plants, and animals, the human genome project and its relation to medical biotechnology, DNA forensics, and pharmaceutical drug discovery, delivery, and FDA approval. The debate surrounding subjects such as cloning, stem cells, and genetically modified foods will also be discussed.
The role of microbes as causative agents of disease in human hosts; the morphological characterization of pathogenic species, classification of communicable diseases and epidemiological aspects. Host-parasite relationship, infection, and host-resistance mechanisms; sero-diagnostic methods in medical practice. Chemotherapy, mode of action of antibiotics, sterilization, disinfection methods and contamination control.